What drugs does KURA make?

KURA has 1 FDA-approved drugs including KOMZIFTI.

What therapeutic areas does KURA focus on?

KURA focuses primarily on Oncology and Metabolic and 1 other therapeutic areas.

← Back

Data updated: Mar 10, 2026

KURA

OncologyMetabolicGastroenterology

Pharma

KURA is a pharmaceutical company focused on Oncology, Metabolic, Gastroenterology. Key products include KOMZIFTI.

2025

Since

Drugs

Trials

Approved (2yr)

Key Drugs

KOMZIFTI

ziftomenib

Oncology

KMT2A 1 indications · 2025

Recent Activity

KOMZIFTI 2025-11-13

Type 1 - New Molecular Entity

SEC Filings ProEarly access

Therapeutic Focus

Score weights: Approved drugs ×3, Phase 3 ×2, Phase 2 ×1, Phase 1 ×0.5

Oncology 88%

1 drugs Phase 3: 1 Phase 2: 3 Phase 1: 7

Metabolic 8%

0 drugs Phase 2: 1

Gastroenterology 4%

0 drugs Phase 1: 1

Pipeline Strength ProEarly access

Competitors ProEarly access

Takeda big-pharma

Oncology, Gastroenterology, Metabolic

Pfizer big-pharma

Oncology, Gastroenterology

ASTELLAS specialty

Oncology, Gastroenterology, Metabolic

Amgen biotech

Oncology, Metabolic, Gastroenterology

EMD SERONO INC biotech

Oncology, Metabolic, Gastroenterology

KURA

Key Drugs

Recent Activity

Therapeutic Focus

Pipeline Strength ProEarly access

Competitors ProEarly access

All Drugs (1)

Active (1)

Discontinued (0)

Company Info